CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...